Home / Who We Help / Pharmaceuticals and Drug Development
Schell IP helps pharmaceutical founders and development teams organize patent decisions around drug candidates, formulations, delivery approaches, and commercialization plans. We connect the proposed technical contribution with the evidence, ownership, and disclosure questions that deserve attention before the next milestone.
Photo: CDC / Unsplash
A program may involve a new composition, a formulation that addresses stability, a manufacturing process, or a particular delivery approach. Those are different patent questions. A useful first step is to explain what changed, how it works, and which experimental results support the proposed scope.
For example, a reformulation project may turn on a particular combination of ingredients and processing conditions rather than the broad goal of improving absorption. We can help structure the invention discussion so counsel can evaluate the actual contribution and meaningful alternatives.
Laboratory notebooks, contract research agreements, university obligations, and assignments help explain where rights may originate. Abstracts, publications, partner data rooms, and planned presentations belong on the same calendar as patent decisions. Patent review and regulatory approval are separate workstreams; one does not establish the other.
We can discuss patent searching, application preparation, prosecution, and portfolio priorities, with appropriate technical and Whiteford colleagues involved as the project requires. A patentability review does not by itself resolve freedom to operate around other parties' claims.
Yes. The specific formulation, supporting disclosure, prior art, and claimed contribution need assessment; a changed ingredient alone does not establish patentability.
Where possible. Ownership, confidentiality, access to results, and publication provisions can affect the later patent plan.
No. Patent rights, third-party rights, and regulatory requirements require separate analysis.
Book a Free Consultation to discuss your research stage and the patent questions that affect the next decision. Arrange a confidential channel before sharing technical results.
Jeff Schell is a patent lawyer and entrepreneur who helps pharmaceutical founders and drug development teams obtain and defend patent rights for their product portfolios. He connects patent strategy with product development, commercialization, and business priorities.
Based in Denver and Boulder, Colorado, Jeff is the founder of Schell IP, which is part of Whiteford, Taylor & Preston, LLP.
Please share only a general description and your timing. Do not submit confidential invention details through this website. A consultation request does not by itself establish an attorney-client relationship.
Learn how the entrepreneurial experience and legal expertise of patent lawyer Jeff Schell provides highly unique advantages for our clients.
